AAV Tropism for Pancreatic Tissues

Targeting the pancreas is often divided into two distinct goals: reaching the endocrine cells (the Islets of Langerhans, like alpha and beta cells for diabetes) or the exocrine cells (acinar cells for pancreatitis or cystic fibrosis).

For the pancreas, the route of administration is the primary driver of success, as systemic IV delivery often sees most of the virus sequestered by the liver.

Serotype	Primary Target	Tropism Level	Optimal Route	Notes
AAV8	Beta cells & Acinar	High	Intraperitoneal / IV	The most widely used natural serotype for the pancreas; targets both endocrine and exocrine cells.
AAV9	Acinar Cells	Moderate/High	Systemic (IV)	Excellent for global distribution; generally outperforms AAV8 in total acinar cell transduction via the bloodstream.
AAV6	Beta cells	Very High	Retrograde Ductal	When injected directly into the pancreatic duct, AAV6 shows superior efficiency in targeting islets/beta cells.
AAV2	Islets & Acinar	Moderate	Local / Direct	The “standard” vector; effective for direct pancreatic injection but less efficient than AAV8 or AAV9 systemically.
AAV4	Beta cells	Moderate	Systemic (IV)	Recently identified in “atlas” studies as having a unique preference for pancreatic beta cells in certain mouse models.
AAV-KP1	Human Islets	Ultra High	Local / Ex vivo	Synthetic; engineered for human kidney/pancreas. Outperforms AAV8 by ~10x in human islet cells.
AAV-DJ	Pancreatic Tissue	High	Local Injection	A synthetic chimera often used in research for its high potency, though limited by high liver “leakage” if given systemically.

Delivery Strategies: Bypassing the Liver

Because the pancreas is highly vascularized, the delivery method determines which cells the AAV actually “sees”:

1. Systemic (IV / IP): AAV8 and AAV9 are the best here. Intraperitoneal (IP) injection is often preferred in animal models as it provides a slower, more localized exposure to the pancreas compared to a tail-vein IV.
2. Retrograde Pancreatic Ductal Infusion: Similar to the salivary gland method, the virus is infused backward through the pancreatic duct. AAV6 is the standout performer for this route, specifically reaching the islets.
3. Direct Intrapancreatic Injection: Highly invasive but ensures the virus stays within the organ. AAV2 and AAV8 are commonly used.

Pancreas-Specific Promoters

To ensure the gene only functions in the correct pancreatic cell type (vital for diabetes research):

• RIP (Rat Insulin Promoter) / hINS: Restricts expression strictly to Beta cells.
• GCG (Glucagon): Restricts expression to Alpha cells.
• PTF1a / Elastase: Targets the Exocrine Acinar cells.
• Pdx1: A broader promoter for pancreatic progenitor cells and mature beta cells.

A Note on AAV-KP1

If your research involves human islet transplantation or Type 1 Diabetes, AAV-KP1 is currently the state-of-the-art synthetic variant. It was developed through directed evolution to specifically solve the problem of low transduction in human pancreatic endocrine cells.